The Results
At present, the pharmaceutical industry has developed to powerful protectors with IP very superiors like +50 or 90. This in theory, would leave prote’ge’ to the individual during many hours without to have to worry about the application of a new dose, but actually this is not thus and must be avoided the prolonged exhibition. This is because each company bases its presented/displayed IP on its own products or clinical studies reason why the final results will be very variable between everyone. There are marks that can be +25 but the real IP of the product is of +15, for example. What it is tried is to standardize this measurement to obtain a real situation in front of the sun since this can turn out to be a risk for the people. From 1996 in Europe, method COLIPA has established the bases of the standardization since it establishes you rule to follow eg: for the determination of the IP of a solar product through diverse factors? Type of skin? Number of volunteers for the clinical test? Amount and technique of application of the product? Solar exposure time? Type of light source? Statistical treatment of the results This allows to have a stricter control in this type of products reason why before acquiring them it would be necessary to consider what type of method uses the manufacturing laboratory and if this one adjusts to the standards, not only the considered ones by the legislation of the country, but those that also talk about the fotoproteccin. However, in the absence of standardization it is probable that each laboratory makes serve its own method. Which are real and necessary minimums IP for each fototipo? Although we must consider the present changes that are occurring in the fotoprotectores, as well as the innovations in the new pharmaceutical forms to improve the galnica of the products, if that there are established minimums for fototipo which they are going to depend on the insolation degree:
